You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
據報國家審計署赴廣東調查 三家藥企假借名義套取資金近41億人幣
《界面新聞》報道,近日獲悉一份由國家審計署出具的廣東省藥品耗材專項審計調查報告,顯示自2023年5月底至7月,國家審計署派出的審計組對廣東省藥品和高值醫用耗材生產經銷使用情況進行專項審計調查。 報告指出廣東省在醫藥市場主體管理、政策執行、藥品監管等方面還存在「暗箱操作」、「脫離實際」及「管理缺位」等問題,需要加以糾正和改進。 報告披露,2021年至2023年5月,廣東省藥品生產總值前50家企業營業總收入1,511.83億元人民幣(下同)、總成本707.61億元、總銷售費用446.17億元,共投入技術開發費用29.5億元,僅爲銷售費用的6.61%,售費用中涉及「推廣」、「諮詢」及「服務」等內容的第三方服務費用289.06億元,佔銷售費用的64.79%。 期內,麗珠製藥(000513.SZ)、一品紅(300723.SZ)和香港上市公司中國中藥(00570.HK)旗下的一方製藥三家藥品生產企業向1,936家第三方商務推廣公司支付費用,假借服務費用等名義套取資金40.77億元,增加藥品綜合成本,推高出廠價格。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account